Interferon beta (IFN-beta)

Study	Exclusion reasons	Rmk	Reference
Coyle, 2014	inadequate or absent control group		Coyle BMJ Open 2014; 4:e004536 10.1136/bmjopen-2013-004536
Richman, 2012	inadequate or absent control group		Richman Neurology. 2012;78(suppl 1):P06.191.
Romero, 2015	case report or case series		Romero J. Neurol. Neurosurg. Psychiatry 2015; 86:587-9 10.1136/jnnp-2014-308113
Shimizu, 2015	case report or case series		Shimizu Clinical and Experimental Neuroimmunology 2015;6:402–408 https://doi.org/10.1111/cen3.12231
Hellwig, 2010	other reason		Hellwig J. Neurol. 2010; 257:580-3 10.1007/s00415-009-5376-z
Fares, 2016	not relevant exposure	Before pregnancy, 23 women (79.3%) were on intramuscular interferon β-1a and received one injection per week. The other 6 women (20.7%) were on subcutaneous interferon β-1a and received three injections per week.	Fares BMJ Open 2016; 6:e011210 10.1136/bmjopen-2016-011210
Kasatkin, 2017	not relevant exposure
Kasatkin, 2017	not relevant outcome	EXCLUDED: continuous variables.	Kasatkin Zh Nevrol Psikhiatr Im S S Korsakova 2017; 117:85-91
Hellwig, 2012	repeat population groups, duplicate reports (most recent study included)		Hellwig, K. Therapeutic Advances in Neurological Disorders 2012; 5:247-. 10.1177/1756285612453192
Amato, 2010	same data already obtained by other studies		Amato Neurology 2010; 75:1794-802 10.1212/WNL.0b013e3181fd62bb
Patti, 2008	same data already obtained by other studies		Patti J. Neurol. 2008; 255:1250-3 10.1007/s00415-008-0909-4
Cuello, 2017	Studies without separate analysis of the considered drug/class from other drugs/class	Four patients became pregnant while receiving DMDs: Avonex® in 1 case, Copaxone® in 1 case, 1 with Rebif®, 1 with Betaferon®: DMDs were discontinued immediately after pregnancy was diagnosed (all in the 1st trimester, mean of 6.5 weeks (3-10)).	Cuello Neurologia 2017; 32:92-98 10.1016/j.nrl.2014.12.015
Fernandez Liguori, 2009	Studies without separate analysis of the considered drug/class from other drugs/class	Immunomodulatory therapy (IMT) was not interrupted before conception in 23 out of 42 pregnancies (54.8%). Out of 65 (46.1%) unplanned pregnancies, 11 (16.9%) were exposed to IMT. => No other details on the nb of exposure to each IMT during pregnancy.	Fernandez Liguori Mult. Scler. 2009; 15:555-62 10.1177/1352458509102366
Buraga, 2014	Studies without separate analysis of the considered drug/class from other drugs/class		Buraga ScientificWorldJournal 2014; 2014:513160 10.1155/2014/513160
Hellwig, 2008	Studies without separate analysis of the considered drug/class from other drugs/class		Hellwig Acta Neurol. Scand. 2008; 118:24-8 10.1111/j.1600-0404.2007.00978.x
Fertl, 2008	Review articles, letter to editor, editorial, comments		Fertl Wien Med Wochenschr 2008; 158:98-109 10.1007/s10354-008-0510-6